[1] SUNG H,FERLAY J,SIEGEL RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA Cancer J Clin,2021,70(1):7-30.
[2] GOUTSOULIAK K,VEERARAGHAVAN J,SETHUNATH V，et al.Towards personalized treatment for early stage HER2-positive breast cancer［J］.Nat Rev Clin Oncol,2020,17(4):233-250.
[3] ABD EDM,PINDER SE,PAISH CE,et al.Expression and co-expression of the members of the epidermal growth factor receptor(EGFR) family in invasive breast carcinoma［J］.Br J Cancer,2004,91(8):1532-1542.
[4] CRISTOFANILLI M,DEMICHELE A,GIORGETTI C,et al.Predictors of prolonged benefit from palbociclib plus fulvestrant in women with endocrine-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in PALOMA-3［J］.Eur J Cancer,2018,104:21-31.
[5] BASHRAHEEL SS,KHERALDINE H,KHALAF S,et al.Metformin and HER2-positive breast cancer:Mechanisms and therapeutic implications［J］.Biomed Pharmacother,2023,162:114676.
[6] CHOONG GM,CULLEN GD,OSULLIVAN CC.Evolving standards of care and new challenges in the management of HER2-positive breast cancer［J］.CA Cancer J Clin,2020,70(5):355-374.
[7] DE VISSER KE,JOYCE JA.The evolving tumor microenvironment:From cancer initiation to metastatic outgrowth［J］.Cancer Cell,2023,41(3):374-403.
[8] CHHABRA Y,WEERARATNA AT.Fibroblasts in cancer:Unity in heterogeneity［J］.Cell,2023,186(8):1580-1609.
[9] SU SC,CHEN JN,YAO HR,et al.CD10GPR77 cancer-associated fibroblasts promote cancer formation and chemoresistance by sustaining cancer stemness［J］.Cell,2018,172(4):841-856.
[10]ERSHAID N,SHARON Y,DORON H,et al.NLRP3 inflammasome in fibroblasts links tissue damage with inflammation in breast cancer progression and metastasis［J］.Nat Commun,2019,10(1):4375.
[11]SUH J,KIM DH,LEE YH,et al.Fibroblast growth factor-2,derived from cancer-associated fibroblasts,stimulates growth and progression of human breast cancer cells via FGFR1 signaling［J］.Mol Carcinog,2020,59(9):1028-1040.
[12]XIE N,TIAN C,WU H,et al.FGFR aberrations increase the risk of brain metastases and predict poor prognosis in metastatic breast cancer patients［J］.Ther Adv Med Oncol,2020,12:1758835920915305.
[13]HANKER AB,GARRETT JT,ESTRADA MV,et al.HER2-overexpressing breast cancers amplify FGFR signaling upon acquisition of resistance to dual therapeutic blockade of HER2［J］.Clin Cancer Res,2017,23(15):4323-4334.
[14]SONNENBLICK A,SALMON-DIVON M,SALGADO R,et al.Reactive stroma and trastuzumab resistance in HER2-positive early breast cancer［J］.Int J Cancer,2020,147(1):266-276.
[15] ZERVANTONAKIS IK,POSKUS MD,SCOTT AL,et al.Fibroblast-tumor cell signaling limits HER2 kinase therapy response via activation of MTOR and antiapoptotic pathways［J］.Proc Natl Acad Sci USA,2020,117(28):16500-16508.
[16] FERNANDEZ-NOGUEIRA P,MANCINO M,FUSTER G,et al.Tumor-associated fibroblasts promote HER2-targeted therapy resistance through FGFR2 activation［J］.Clin Cancer Res,2020,26(6):1432-1448.
[17] BRAGADO P,FERNANDEZ-NOGUEIRA P,CARBO N,et al.Unraveling the role of fibroblasts,FGF5 and FGFR2 in HER2-targeted therapies resistance and tumor progression［J］.Oncotarget,2020,11(49):4541-4543.
[18] MARUSYK A,TABASSUM DP,JANISZEWSKA M,et al.Spatial proximity to fibroblasts impacts molecular features and therapeutic sensitivity of breast cancer cells influencing clinical outcomes［J］.Cancer Res,2016,76(22):6495-6506.
[19] MUKHERJEE A,BILECZ AJ,LENGYEL E.The adipocyte microenvironment and cancer［J］.Cancer Metastasis Rev,2022,41(3):575-587.
[20] BOCIAN-JASTRZEBSKA A,MALCZEWSKA-HERMAN A,KOS-KUDLA B.Role of leptin and adiponectin in carcinogenesis［J］.Cancers(Basel),2023,15(17):4250.
[21] DOWNER MA,GRIFFIN MF,MORGAN AG,et al.Understanding the role of adipocytes and fibroblasts in cancer［J］.Ann Plast Surg,2023,91(6):779-783.
[22] LEE-RUECKERT M,CANYELLES M,TONDO M,et al.Obesity-induced changes in cancer cells and their microenvironment:Mechanisms and therapeutic perspectives to manage dysregulated lipid metabolism［J］.Semin Cancer Biol,2023,93:36-51.
[23] HE JY,WEI XH,LI SJ,et al.Adipocyte-derived IL-6 and leptin promote breast cancer metastasis via upregulation of Lysyl Hydroxylase-2 expression［J］.Cell Commun Signal,2018,16(1):100.
[24] GIORDANO C,VIZZA D,PANZA S,et al.Leptin increases HER2 protein levels through a STAT3-mediated up-regulation of Hsp90 in breast cancer cell［J］.Mol Oncol,2013,7(3):379-391.
[25] GRINER SE,WANG KJ,JOSHI JP,et al.Mechanisms of adipocytokine-mediated Trastuzumab resistance in HER2-positive breast cancer cell lines［J］.Curr Pharmacogenomics Person Med,2013,11:31-41.
[26] DUONG MN,CLERET A,MATERA E,et al.Adipose cells promote resistance of breast cancer cells to trastuzumab-mediated antibody-dependent cellular cytotoxicity［J］.Breast Cancer Res,2015,17:57.
[27] GENESTE A,DUONG MN,MOLINA L,et al.Adipocyte-conditioned medium induces resistance of breast cancer cells to lapatinib［J］.BMC Pharmacol Toxicol,2020,21(1):61.
[28] BARROSO-SOUSA R,BARRY WT,GUO H,et al.The immune profile of small HER2-positive breast cancers:a secondary analysis from the APT trial［J］.Ann Oncol,2019,30(4):575-581.
[29] LUEN SJ,SALGADO R,FOX S,et al.Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel:a retrospective analysis of the CLEOPATRA study［J］.Lancet Oncol,2017,18(1):52-62.
[30] PERNAS S,TOLANEY SM.Targeting HER2 heterogeneity in early-stage breast cancer［J］.Curr Opin Oncol,2020,32(6):545-554.
[31] SOLINAS C,CEPPI M,LAMBERTINI M,et al.Tumor-infiltrating lymphocytes in patients with HER2-positive breast cancer treated with neoadjuvant chemotherapy plus trastuzumab,lapatinib or their combination:A meta-analysis of randomized controlled trials［J］.Cancer Treat Rev,2017,57:8-15.
[32] XU M,DU XX,LIU MY,et al.The tumor immunosuppressive microenvironment impairs the therapy of anti-HER2/neu antibody［J］.Protein Cell,2012,3(6):441-449.
[33] WU SY,FU T,JIANG YZ,et al.Natural killer cells in cancer biology and therapy［J］.Mol Cancer,2020,19(1):120.
[34] MUNTASELL A,ROJO F,SERVITJA S,et al.NK cell infiltrates and HLA class I expression in primary HER2 breast cancer predict and uncouple pathological response and disease-free survival［J］.Clin Cancer Res,2019,25(5):1535-1545.
[35] MUNTASELL A,SERVITJA S,CABO M,et al.High numbers of circulating CD57 NK cells associate with resistance to HER2-specific therapeutic antibodies in HER2 primary breast cancer［J］.Cancer Immunol Res,2019,7(8):1280-1292.
[36] MUNTASELL A,CABO M,SERVITJA S,et al.Interplay between natural killer cells and Anti-HER2 antibodies:perspectives for breast cancer immunotherapy［J］.Front Immunol,2017,8:1544.
[37] AGHAZADEH S,YAZDANPARAST R.Activation of STAT3/HIF-1α/Hes-1 axis promotes trastuzumab resistance in HER2-overexpressing breast cancer cells via down-regulation of PTEN［J］.Biochim Biophys Acta Gen Subj,2017,1861(8):1970-1980.
[38] KARAKASHEV SV,REGINATO MJ.Hypoxia/HIF1α induces lapatinib resistance in ERBB2-positive breast cancer cells via regulation of DUSP2［J］.Oncotarget,2015,6(4):1967-1980.
[39] WU YY,TRAN T,DWABE S,et al.A83-01 inhibits TGF-β-induced upregulation of Wnt3 and epithelial to mesenchymal transition in HER2-overexpressing breast cancer cells［J］.Breast Cancer Res Treat,2017,163(3):449-460.
[40] TAHER MY,DAVIES DM,MAHER J.The role of the interleukin(IL)-6/IL-6 receptor axis in cancer［J］.Biochem Soc Trans,2018,46(6):1449-1462.
[41] RODRIGUEZ-BARRUECO R,YU JY,SAUCEDO-CUEVAS LP,et al.Inhibition of the autocrine IL-6-JAK2-STAT3-calprotectin axis as targeted therapy for HR-/HER2+ breast cancers［J］.Genes Dev,2015,29(15):1631-1648.
[42] KORKAYA H,KIM G,DAVIS A,et al.Activation of an IL6 inflammatory loop mediates trastuzumab resistance in HER2+ breast cancer by expanding the cancer stem cell population［J］.Mol Cell,2012,47(4):570-584.
[43] LOI S,GIOBBIE-HURDER A,GOMBOS A,et al.Pembrolizumab plus trastuzumab in trastuzumab-resistant,advanced,HER2-positive breast cancer(PANACEA):a single-arm,multicentre,phase 1b-2 trial［J］.Lancet Oncol,2019,20(3):371-382.
[44] EMENS LA,ESTEVA FJ,BERESFORD M,et al.Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated,HER2-positive advanced breast cancer(KATE2):a phase 2,multicentre,randomised,double-blind trial［J］.Lancet Oncol,2020,21(10):1283-1295.
[45] KNUTSON KL,BLOCK MS,NORTON N,et al.Rapid generation of sustainable HER2-specific T-cell immunity in patients with HER2 breast cancer using a degenerate HLA class II epitope vaccine［J］.Clin Cancer Res,2020,26(5):1045-1053.
[46] CROSBY EJ,GWIN W,BLACKWELL K,et al.Vaccine-induced memory CD8 T cells provide clinical benefit in HER2 expressing breast cancer:a mouse to human translational study［J］.Clin Cancer Res,2019,25(9):2725-2736.
[47] PEREZ-GARCIA J,MUNOZ-COUSELO E,SOBERINO J,et al.Targeting FGFR pathway in breast cancer［J］.Breast,2018,37:126-133.